Form 4: Adaptive Bio CPO Sells Shares After Option Exercise

Adaptive Biotechnologies' Chief People Officer, Francis Lo, executed a pre-planned sale of 113,890 shares after exercising stock options.

Summary

• Francis Lo, Chief People Officer of Adaptive Biotechnologies Corp (ADPT), engaged in transactions on December 15, 2025, under a Rule 10b5-1 trading plan adopted on September 15, 2025.
• Lo exercised stock options to acquire a total of 97,022 shares of common stock: 37,750 shares at $7.80, 19,423 shares at $8.46, and 39,849 shares at $3.99.
• Concurrently, Lo sold 113,890 shares of common stock at a weighted-average price of $15.57, with individual sales ranging from $15.37 to $16.03.
• Following these transactions, Lo's direct beneficial ownership stands at 315,978 shares, with an additional 2,500 shares held indirectly by a spouse.
• Remaining derivative securities include 113,250 stock options exercisable at $7.80, 109,176 stock options exercisable at $8.46, and 110,175 stock options exercisable at $3.99.

Sentiment

Score: 5

Explanation: Neutral. The filing reports routine insider transactions (option exercises and sales) executed under a pre-planned Rule 10b5-1 plan. This is a standard disclosure and does not inherently indicate positive or negative company performance, but rather personal financial management by an executive.

Positives

• The Chief People Officer exercised options at significantly lower prices ($3.99, $7.80, $8.46) compared to the sale price ($15.57), indicating a profitable transaction for the executive.
• The transactions were executed under a pre-established Rule 10b5-1 trading plan, demonstrating planned and transparent insider trading activity.

Negatives

• The Chief People Officer sold a substantial number of shares (113,890), reducing their direct beneficial ownership in the company.
• The net effect of the transactions (acquiring 97,022 shares and selling 113,890 shares) resulted in a decrease in direct share holdings.

Risks

• NA

Future Outlook

NA

Industry Context

This Form 4 filing details routine insider transactions for a biotechnology company executive. Such transactions are common and typically reflect personal financial planning rather than specific company-related news or broader industry trends, especially when executed under a Rule 10b5-1 plan.

Comparison to Industry Standards

• NA

Related Party Transactions

• The transactions involve the Chief People Officer of Adaptive Biotechnologies Corp, which is a related party transaction by definition of insider trading.

Stakeholder Impact

• Shareholders may observe a reduction in direct insider ownership, which could be interpreted differently depending on individual investment philosophies. However, the pre-planned nature of the transactions under Rule 10b5-1 suggests a lack of new, material information driving the sale.

Next Steps

• NA

Key Dates

Recommendation

This Form 4 filing details a pre-planned insider transaction involving the exercise of stock options and subsequent sale of shares by a Chief People Officer. Such transactions, especially when executed under a Rule 10b5-1 plan, are generally considered routine and do not typically signal a change in the company's fundamental outlook or performance. Therefore, it does not provide a basis for a 'buy' or 'sell' recommendation, and a 'hold' stance is appropriate as this filing alone does not alter the investment thesis for Adaptive Biotechnologies Corp.

Keywords

Adaptive Biotechnologies, ADPT, Francis Lo, Chief People Officer, Insider Trading, Form 4, Stock Options, Share Sale, Rule 10b5-1, Beneficial Ownership